单位：[1]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China[2]Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27607, United States[3]Joint Department of Biomedical Engineering and Comparative Medicine Institute, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, North Carolina 27599 and 27607, United States[4]College of Chemistry and Environmental Science, Chemical Biology Key Laboratory of Hebei Province, Analytical Chemistry Key Laboratory of Hebei Province, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Hebei University, Baoding, Hebei 071002, China[5]Department of Pathology, China-Japan Friendship Hospital, Peking 100029, China[6]Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China
Acute liver failure is a critical condition characterized by global hepatocyte death and often time needs a liver transplantation. Such treatment is largely limited by donor organ shortage. Stem cell therapy offers a promising option to patients with acute liver failure. Yet, therapeutic efficacy and feasibility are hindered by delivery route and storage instability of live cell products. We fabricated a nanoparticle that carries the beneficial regenerative factors from mesenchymal stem cells and further coated it with the membranes of red blood cells to increase blood stability. Unlike uncoated nanoparticles, these particles promote liver cell proliferation in vitro and have lower internalization by macrophage cells. After intravenous delivery, these artificial stem cell analogs are able to remain in the liver and mitigate carbon tetrachloride induced liver failure in a mouse model, as gauged by histology and liver function test. Our technology provides an innovative and off-the-shelf strategy to treat liver failure.
基金：
National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL123920, HL137093]; NC State University Chancellor's Faculty Excellence Program; NC State Chancellor's Innovation Fund; University of North Carolina General Assembly Research Opportunities Initiative grant; Scientific and Technological Project of Henan Province, China [152102410063]; Henan Province Commission of Heath and Family Planning [2015027]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL137093, R01HL123920] Funding Source: NIH RePORTER
第一作者单位：[1]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China[2]Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27607, United States[3]Joint Department of Biomedical Engineering and Comparative Medicine Institute, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, North Carolina 27599 and 27607, United States
共同第一作者：
通讯作者：
通讯机构：[1]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China[2]Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27607, United States[3]Joint Department of Biomedical Engineering and Comparative Medicine Institute, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, North Carolina 27599 and 27607, United States
推荐引用方式(GB/T 7714)：
Liang Hongxia,Huang Ke,Su Teng,et al.Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure[J].ACS NANO.2018,12(7):6536-6544.doi:10.1021/acsnano.8b00553.
工程技术